Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Obamacare enrollment declines as US subsidies expire - 2Web designers for Independent ventures
- 35 Language Learning Applications
- 4British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- 5EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- Shipping: The Corridors of Trade and the Coming of Another Period
- Treasure trove found in Egyptian tomb solves ancient mystery
- Iran slams UN nuclear watchdog for failing to condemn Bushehr attacks
- Select Your Cherished Fish
- ‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- Northern lights chances rise for Christmas as space weather remains unsettled
- Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
- Mom finds out she has cancer after noticing something was off while breastfeeding
- IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses
